Shares of Shilpa Medicare rose 3.31% to Rs 291.55 after the drugmaker launched capecitabine (Capebel) dispersible tablets (DT), a technology that disperses faster in 90 seconds for the treatment of colorectal and metastatic breast cancer.
The new brand name of Shilpa is Capebel, and patients will be required to drop the Capecitabine tablets in 100 ml water, allow the tablets to dissolve, and then drink the dissolved solution. Hence, patients must take 7-8 tablets in 100 ml water twice daily with dissolved tablets.
- India sees minimal impact from US trade policies, but risks persist: UBI Report
- Perplexity in Early Funding Talks at $18 Billion Valuation
- Toyota to Launch First India R&D Hub, Plans 1,000 Engineers & EV Expansion by 2027
- Trump Announces Upcoming US-Ukraine Minerals Deal
- Mazagon Dock, Goa Tie Up for AI-Based Disaster Management; Shares Fall 1%
The product is backed by the required scientific evidence and comparative bioequivalence studies and is approved by the Central Drugs Standard Control Organisation (CDSCO). Moreover, the other tablets are coming soon, named Capebel 1 gm DT, in various international markets through its partners and clients.
On a consolidated basis, the company’s net loss was Rs 18.66 crore compared with a net profit of Rs 19.96 crore in the September 21 quarter over the September quarter. Net sales went down 11% yearly to Rs 262.91 crore in Q2FY23.
